Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

PURPOSE: To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC). PATIENTS AND METHODS: Chemotherapy-naïve patients with mCRC, received bevacizumab (5 mg/kg every 2 weeks d(1)), oxaliplatin (85 mg/m(2 )on d(1)), leucovorin (20...

Descripción completa

Detalles Bibliográficos
Autores principales: Emmanouilides, Christos, Sfakiotaki, Georgia, Androulakis, Nikolaos, Kalbakis, Kostas, Christophylakis, Charalambos, Kalykaki, Antonia, Vamvakas, Lambros, Kotsakis, Athanasios, Agelaki, Sofia, Diamandidou, Eleni, Touroutoglou, Nikolaos, Chatzidakis, Adam, Georgoulias, Vassilis, Mavroudis, Dimitris, Souglakos, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894803/
https://www.ncbi.nlm.nih.gov/pubmed/17537235
http://dx.doi.org/10.1186/1471-2407-7-91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894803/
https://www.ncbi.nlm.nih.gov/pubmed/17537235
http://dx.doi.org/10.1186/1471-2407-7-91

Ejemplares similares